
G1 Therapeutics Inc is a biotechnology business based in the US. G1 Therapeutics shares (GTHX) are listed on the NASDAQ and all prices are listed in US Dollars. G1 Therapeutics employs 148 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in G1 Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – GTHX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Our top pick for
Beginners

Our top pick for
Building a portfolio

Our top pick for
Advanced traders

G1 Therapeutics stock price (NASDAQ: GTHX)
Use our graph to track the performance of GTHX stocks over time.G1 Therapeutics shares at a glance
Latest market close | $4.94 |
---|---|
52-week range | $3.84 - $24.12 |
50-day moving average | $5.22 |
200-day moving average | $9.87 |
Wall St. target price | $39.50 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-4.03 |
Buy G1 Therapeutics shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy G1 Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
G1 Therapeutics price performance over time
Historical closes compared with the close of $4.94 from 2022-06-30
1 week (2022-06-24) | -10.83% |
---|---|
1 month (2022-06-02) | 9.05% |
3 months (2022-03-29) | N/A |
6 months (2021-12-31) | -51.62% |
1 year (2021-07-02) | -76.96% |
---|---|
2 years (2020-07-02) | -77.07% |
3 years (2019-07-02) | 30.13 |
5 years (2017-06-30) | 17.44 |
G1 Therapeutics financials
Revenue TTM | $24.2 million |
---|---|
Gross profit TTM | $29.5 million |
Return on assets TTM | -38.84% |
Return on equity TTM | -99.03% |
Profit margin | 0% |
Book value | $2.35 |
Market capitalisation | $236.6 million |
TTM: trailing 12 months
G1 Therapeutics share dividends
We're not expecting G1 Therapeutics to pay a dividend over the next 12 months.
G1 Therapeutics share price volatility
Over the last 12 months, G1 Therapeutics's shares have ranged in value from as little as $3.84 up to $24.12. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while G1 Therapeutics's is 2.0277. This would suggest that G1 Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
G1 Therapeutics overview
G1 Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co.
G1 Therapeutics in the news
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Got $500? 3 Absurdly Cheap Healthcare Stocks That Are Set to Skyrocket
Frequently asked questions
What percentage of G1 Therapeutics is owned by insiders or institutions?Currently 9.027% of G1 Therapeutics shares are held by insiders and 68.269% by institutions. How many people work for G1 Therapeutics?
Latest data suggests 148 work at G1 Therapeutics. When does the fiscal year end for G1 Therapeutics?
G1 Therapeutics's fiscal year ends in December. Where is G1 Therapeutics based?
G1 Therapeutics's address is: 700 Park Offices Drive, Research Triangle Park, NC, United States, 27709 What is G1 Therapeutics's ISIN number?
G1 Therapeutics's international securities identification number is: US3621LQ1099 What is G1 Therapeutics's CUSIP number?
G1 Therapeutics's Committee on Uniform Securities Identification Procedures number is: 3621LQ109
More guides on Finder
-
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
-
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
-
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
-
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
-
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
-
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
-
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
-
How to buy Warrantee (WRNT) stock when it goes public
Everything we know about the Warrantee IPO, plus information on how to buy in.
-
How to buy Treasure Global (TGL) stock when it goes public
Everything we know about the Treasure Global IPO, plus information on how to buy in.
-
How to buy BIOLIFE4D (SAVU) stock when it goes public
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
Ask an Expert